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Transcatheter pulmonary valve implantation has been a well-known me-
thod for more than a decade, but there are still many challenging cases 
when a personalized solution is needed. We report a case of a 15-year-old 
female patient with tetralogy of Fallot, who underwent a  surgical cor-
rection during infancy. Because of progressive pulmonary regurgitation, 
stenosis, and right ventricle dilatation, transcatheter pulmonary valve 
implantation in the native right ventricle outflow tract (RVOT) using Ed-
wards SAPIEN valve was performed. A “landing zone” was created prior 
to the intervention of stenting the RVOT and the right pulmonary artery.
The transcatheter approach for pulmonary valve replacement in a na-
tive RVOT is a reasonable alternative to the surgical approach.
Keywords: Edwards SAPIEN valve, transcatheter pulmonary valve im-
plantation, Tetralogy of Fallot, native RVOT
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INTRODUCTION
Twenty years ago, Bonhoeffer and colleagues report-
ed the first in-human transcatheter pulmonary valve 
implantation (1). A  12-year-old male patient with 
stenosis and insufficiency of a  prosthetic conduit 
between the  right ventricle (RV) and pulmonary 
arteries (PA) was treated with a bovine jugular ve-
nous valve sutured into a stent and then crimped on 
a balloon (Melody® valve, Medtronic, Minneapolis, 
MN, United States of America). This marked a par-
adigm shift in treating failed RV-PA conduits. How-
ever, many patients with right ventricle outflow tract 
(RVOT) dysfunction do not have a conduit. In such 
cases, transcatheter pulmonary valve implantation 
(TPVI) must be performed in the native RVOT. In 
these patients, anchoring of the transcatheter heart 
valve (THV) in often non-calcified RVOT can be 
challenging. The  first successful TPVI in a  native 
RVOT after a  surgical repair of Tetralogy of Fallot 
(TOF) with transannular patch was described in 
2008 (2). One common way to perform this proce-
dure is to create a  “landing zone” for the  THV by 
pre-stenting the  native RVOT. Several case series 
have been published using the Melody valve as well 
as the Edwards SAPIEN valve (Edwards Lifescienc-
es, Irvine, CA) (3). We report the first experience of 
TPVI in a native RVOT in Latvia.
CASE REPORT
We report the case of a patient with TOF, who at 
the age of five months underwent a surgical cor-
rection – the closure of a ventricular septal defect 
with pericardial patch, resection of infundibular 
stenosis and transannular patch. The  postopera-
tive period was unremarkable. The patient under-
went regular follow-up in a cardiology outpatient 
unit. Gradually, transthoracic echocardiography 
(TTE) revealed progressive dilatation of the  RV 
and tricuspid valve regurgitation (TVR) with 
a  peak gradient of 43  mmHg. At the  age of 15, 
the  patient was still asymptomatic and was not 
receiving any medication. Holter monitoring did 
not show any arrhythmias. Cardiac MRI showed 
gradual RV dilatation (a 10% increase in a 3-year 
period). In the  last MRI, the  RV end-diastolic 
volume was 154  ml/m2, the  end-systolic volume 
64 ml/m2, ejection fraction 62%. Late gadolinium 
enhancement of the RVOT myocardium, bilater-
al mild proximal PA stenoses, moderate tricuspid 
regurgitation, and free pulmonary valve regurgi-
tation (PVR) (42%) were observed.
The decision was made to perform the  TPVI 
because of progressive RV dilatation, RV volume 
>  150ml/m2 and severe PVR. Before the  proce-
dure, cardiac computer tomography (CT) was 
done. In CT,  RVOT diameter was 26  mm and 
an appropriate distance between RVOT and cor-
onary arteries was seen (Figs. 1 and 2). Therefore, 
RVOT stenting, preceded by transcatheter pulmo-
nary valve implantation in the native RVOT, was 
performed.
Mounted on a  20  mm balloon-in-balloon 
catheter, RVOT stenting with a 48 mm XXL An-
draStent (Andramed, Reutlingen, Germany) 
Fig. 1. CT image showing the size of the RVOT and the distance from 
the left coronary artery
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was implanted successfully two months prior to 
re-valving in order to allow tissue in-growth and 
stabilization of the stent. Furthermore, the distal 
part of the  stent was covering the  proximal part 
of the  right PA, to ensure stable position. A  de-
tailed description of the  procedure with addi-
tional pictures is given in Appendix 1. Aspirin 
100  mg once daily was started. After the  proce-
dure, TTE showed severe pulmonary regurgita- 
tion (Fig. 3).
A 26 mm balloon-expandable Edwards SA-
PIEN 3 THV (Edwards Lifesciences, Irvine, CA) 
was implanted in the  AndraStent (Appendix  2). 
Post-implantation angiography showed neither 
central or paravalvular pulmonary regurgitation, 
nor compression of the  coronary arteries. After 
the procedure, RVOT maximal peak systolic gra-
dient was 12 mmHg. The patient was discharged 
from the hospital three days after the procedure.
At 6-month post-procedural follow-up, the pa-
tient was asymptomatic and doing regular physi-
cal activities. TTE showed RVOT maximal peak 
systolic gradient of 22  mmHg, no pulmonary 
regurgitation, and mild TVR with a  peak gradi-
ent of 33 mmHg. The result of the procedure was 
successful.
Fig. 2. CT image showing the shape and the size of the RVOT
Fig. 3. Echocardiography image showing free pulmonary regurgitation after 
stent implantation
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DISCUSSION
For many years, surgical pulmonary valve implan-
tation has been the  gold standard for the  treat-
ment of free pulmonary regurgitation in the native 
RVOT. However, during the  last decade transcath-
eter re-valving has been proven to be an efficient 
alternative to the surgical approach in degenerated 
RV-PA conduits, and this has led to the expansion 
of the technique to the native RVOT (4). This percu-
taneous approach has several advantages compared 
to surgery, which implies repeated sternotomy, car-
diopulmonary bypass, and a  longer recovery time. 
One limitation of transcatheter pulmonary valve im-
plantation is the need for a proper landing zone for 
anchoring, which may not be present in the large na-
tive RVOT (5). Other limitations include issues with 
positioning the THV, endocarditis, and paravalvular 
regurgitation (5). The present case report shows how 
this is safe and efficient in carefully selected patients.
CONCLUSIONS
Transcatheter approach for pulmonary valve re-
placement in a native RVOT could be a reasonable 
alternative to the  surgical approach. The  decision 
should be made on a case-by-case basis, consider-
ing all anatomical variations. Although at present 
it is an off-label method, it is used more frequently 
and found to be safe for a  selected patient group, 
often after pre-stenting of the RVOT.
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PERKATETERINĖ PLAUČIŲ ARTERIJOS 
EDWARDS SAPIEN VOŽTUVO IMPLANTACIJA 
PACIENTO DSNT: PIRMOJI PATIRTIS 
LATVIJOJE
Santrauka 
Perkateterinė plaučių arterijos vožtuvo implantaci-
ja – daugiau nei dešimtmetį žinomas metodas, tačiau 
klinikinėje praktikoje susiduriama su iššūkiais, kai rei-
kia priimti individualų sprendimą. Pristatome 15 m. 
amžiaus pacientės, kuriai diagnozuota Fallot tetrada ir 
kūdikystėje taikytas chirurginis gydymas, atvejį. Esant 
progresuojančiai plautinei regurgitacijai, stenozei ir de-
šiniojo skilvelio išsiplėtimui, buvo atlikta perkateterinė 
plaučių arterijos Edwards SAPIEN vožtuvo implantacija 
pacientės dešiniojo skilvelio nutekėjimo trakte (DSNT) 
(angl. right ventricle outflow tract, RVOT). Prieš sten-
tuojant DSNT ir dešiniąją plaučių arteriją, buvo sukurta 
„nusileidimo zona“. Perkateterinis plaučių arterijos vož-
tuvo keitimas paciento DSNT yra tinkama alternatyva 
chirurginiam gydymui.
Raktažodžiai: Edwards SAPIEN vožtuvas, perka-
teterinė plaučių arterijos vožtuvo implantacija, Fallot 
tetrada, paciento DSNT 
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Appendix 1
PRE-STENTING
A femoral vein and artery were cannulated. A Lunderquist guidewire was placed in an artery of the lower 
pulmonary lobe. Pulmonary angiography was done using a Multi-Track catheter (NuMed Inc, Hopkin-
ton, NY). Next, a 20 mm × 30 mm balloon was positioned in the RVOT. The balloon was inflated during 
simultaneous selective coronary contrast injection. The  purpose of this was to confirm that there was 
a waist on the balloon indicating that the anchoring of the stent was possible and that there was no com-
pression of the coronary arteries (Fig. 1). Then a balloon expandable 48 mm XXL AndraStent (Andramed, 
Reutlingen, Germany) mounted on a 20 mm balloon catheter was implanted in the RVOT and the right 
PA (Fig. 2, 3). After the stent deployment, selective coronary arteriograms were done to confirm patent 
flow (Fig. 4). A 7 Fr Multi-Track catheter was inserted in the PA and control PA angiography was done.
Fig. 1. Balloon in the  RVOT with 
a waist and normal flow in LCA
Fig. 2. Positioning of the  bare metal 
stent in RVOT and the right PA
Fig. 3. Bare metal stent in the RVOT 
and the right PA during balloon in-
flation
Fig. 4. Selective LCA arteriogram af-
ter stent deployment confirms patent 
flow
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Appendix 2
TRANSCATHETER PULMONARY VALVE IMPLANTATION 
A femoral vein was cannulated and Lunderquist guidewire placed in a peripheral PA. A long insertion 
sheath was positioned in the RVOT and 48 mm XXL AndraStent was implanted using the 22 mm double 
balloon technique (Fig. 5). Selective LAD coronarography was done after the stent implantation and nor-
mal flow in the LCA was seen (Fig. 6). RVOT angiography was repeated. The sheath in the femoral vein 
was exchanged for a 14Fr eSheath (Edwards Lifesciences, Irvine, CA, USA) and a 26 mm Edwards XT 
THV mounted on the delivery system was introduced to the RVOT (Fig. 7). The THV was deployed in 
the CP stent during rapid pacing 180 beat-per-minute (Fig. 8 and 9). Next, the valve position was checked 
by pulmonary angiogram (Fig. 10). No paravalvular leak was seen in the control angiography. The delivery 
system was removed and the skin closed using a figure-of-eight stich. 
Fig. 5. 48 mm XXL AndraStent was 
implanted using the  22  mm double 
balloon technique
Fig. 6. Selective LAD arteriogram after 
stent implantation confirms patent flow
Fig. 7. 26  mm Edwards XT THV 
mounted on the delivery system
Fig. 8. THV deployment in the CP stent
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Fig. 10. Pulmonary angiogram after 
THV implantation
Fig. 9. THV deployment in the  CP 
stent
